Press

Invitation to presentation of Acarix´s third quarter report 2022

15 Nov

Acarix will publish its third quarter results on Wednesday 16 November 2022 at 08.00 am (CEST). A live webcast will be held at 16.30 (CEST) the same day, where CEO Helen Ljungdahl Round and CFO Christian Lindholm will present the report. The presentation ends with a Q&A together with Redeye's analysts, where you can ask the company questions via the form on the live page.

The webcast will be available at https://www.redeye.se/events/853972/live-q-acarix-2

The presentation will be available at https://www.acarix.com/for-investors/investor-presentations after publication of the report.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com 
Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Invitation to presentation of Acarix´s third quarter report 2022

Tags:
,
Newer Full focus on the US market with strong interest from healthcare providers, reimbursement code in place and collaboration with ACC
Back to list
Older Article published: Improved pre-test likelihood estimation of coronary artery disease using phonocardiography

Related Posts